News

Quotient Sciences announces second US acquisition: QS Pharma

Quotient Sciences, the early phase drug development services provider, today announces that it has acquired QS Pharma, the contract development and manufacturing organisation (CDMO), based near Philadelphia, US, from Charles River Laboratories International, Inc.

Quotient Clinical expands into USA through acquisition of SeaView Research, the specialist clinical pharmacology business

Quotient Sciences, the early phase drug development services provider, today announces that it has acquired SeaView Research.

Quotient’s Simon Lee elected as Secretary of EUCROF

Quotient Sciences, the innovative provider of early phase drug development services, is pleased to announce that Chief Compliance Officer, Simon Lee, has been elected as Secretary of the European CRO Federation (“EUCROF”).